Jonas Willmann, MD

Radiation Oncologist @Unispital_USZ | former research scholar @MSKCancerCenter | interested in 🫁, reirradiation & oligometastatic disease

[Jonas Willmann, MD @jonas_willmann]

Current classifications of OMD assign one state per patient. But within the same patient, lesions respond, persist, and progress on divergent paths.
We propose metastatic trajectories – a lesion-level framework to guide local + systemic therapy in metastatic NSCLC.
📄 @JCO_ASCO

[Memorial Sloan Kettering Radiation Oncology @MSK_RadOnc]

New in @JCO_ASCO from @IyengarPuneeth and colleagues: proposing "metastatic trajectories," a lesion-level framework for metastatic NSCLC, recognizing that different metastases within the same patient can evolve along divergent biological paths.

Read more: https://t.co/8xhlJKx8YH

[ESTRO @ESTRO_RT]

Just published in the #GreenJournal: Leveraging the potential of prospective registries for radiation oncology research: 5-year experience from the
@EORTC-ESTRO #radiotherapy infrastructure for Europe (E2-RADIatE) project
👉 Read the abstract: https://t.co/fReo0jxxpC

[Aadel Chaudhuri, MD PhD @aadel_chaudhuri]

Excited to share our latest paper out today in @CCR_AACR, led by first authors Ayesha Hashmi, Jessica Linford and Pradeep Chauhan (@pradeep198212) in my lab @MayoRadOnc @MayoCancerCare @MayoClinic.

https://t.co/BARU2qs7Kj

[Shankar Siva @_ShankarSiva]

The primary is the source of first progression in >50% of cases of #lungcancer patients, and TRACERx showed us that in 32% of NSCLC the primary polyclonally seeds metastases. In our @IASLC consensus, now in JTO https://t.co/9LzfFi4ICc, makes the case for eradicating it with #radiotherapy. The EGFRm phase III data are the most compelling OS 34.4 vs 26.2 months with TKI+RT. There are still unresolved questions in the non-AGA population. We are opening the phase III PRIME-LUNG trial https://t.co/4J4JsgWu31 @TROGfightcancer @TOGAANZ to answer this question! #radonc

[ESTRO @ESTRO_RT]

New data on #oligometastatic #ProstateCancer from #ESTRO26:
1️⃣EXTEND: ctDNA= a powerful prognostic tool, though MDT benefits patients regardless of ctDNA status
2️⃣OLIGOPELVIS-2: Salvage nodal RT to para-aortic nodes has manageable long-term side effects.
👉https://t.co/1kr7sW0i0s

[Toni Choueiri, MD @DrChoueiri]

Detecting lung cancer 5 years before it happens, in @CellCellPress courtesy of the @CharlesSwanton group.

Astonishing translational work !

https://t.co/EvUmIGVLgs

[Alessandro Di Federico @DiFedericoMD]

What does chemo add to immunotherapy in pts w/ PD-L1-high NSCLC?
In our meta-analysis of 24 trials w/ reconstructed individual patient data, we observed a meaningful improvement in both median PFS (11.3 vs 6.8 months, HR 0.74) and OS (29.2 vs 19.8 months, HR 0.67) w/ chemo-ICI.

[Giannis Mountzios @g_mountzios]

What a happy coincidence!
While presenting intracranial efficacy data from DeLLphi-304 in #ASCO26, #Tarlatamab was officially approved in EU!!

✅ In ITT: CNS mPFS NR vs 7.8 m, HR=0.54
✅ In BM per mRANO: CNS mPFS 6.5 vs 4.2m, HR=0.4
✅ mOS=13.9 vs 6.8, HR=0.51, independent of baseline BM!

A new SoC, hope that all #SCLC patients will soon have access!!

#some #LCSM @OncoAlert @OncBrothers
@OncLive @PortalOnconews @SclcSMASHERS
@myESMO @ASCO @IASCL @PeerView

[Alfredo Addeo MD @Alfdoc2]

Negative phase III trial of concurrent thoracic RT in ES-SCLC receiving chemoimmunotherapy.
TRT was initiated early (between cycles 2 and 3), and failed to improve outcomes:
• Median OS 10.0 vs 11.8 months
• No improvement in response rate
• More adverse events and treatment-related deaths While disappointing, these results should not be extrapolated to all consolidative TRT strategies. One key difference from SAKK 15/19 is timing: RT here was delivered concurrently with ongoing chemoimmunotherapy, whereas SAKK 15/19 administers TRT after completion of induction treatment and no major toxicity was detected
Perhaps the lesson is not that thoracic RT has no role, but that timing matters. https://t.co/njhvrV4590
#ASCO26 #SCLC #LungCancer #Radiotherapy

[Edward Christopher "Chris" Dee, MD @EChrisDee]

Excellent poster by @militspatel stellar student in our group, on genomic determinants of metastatic urothelial #cancer @ASCO #asco2026

Thank you Drs @IyengarPuneeth @HimanshuNagarMD @jjnaylor02 @jonas_willmann for guidance

[PDBrown @PDBrownOnc]

ASCO2026: Asymptomatic brain met EGFR/ALK NSCLC any benefit upfront cranial RT on this Randomized trial?
- Upfront RT ↑↑ brain control, no benefit PFS, OS
- Selection criteria high risk (e.g. larger size) for upfront RT is key
https://t.co/1CM31nbxeL

[Mario Balsa @MarioBalsaMD]

🫁 Metastatic trajectories in NSCLC: redefining local + systemic therapy through disease evolution! @JCO_ASCO
https://t.co/XcpEhaGHML

▪️ Genomics + ctDNA + radiomics + functional imaging
▪️ Defines progression by pace, pattern, organotropism & resistance mechanisms
▪️ Adaptive strategies: escalate, switch, consolidate or locally ablate
▪️ Could reshape biomarker-driven platform trials in mNSCLC

Not all metastases follow the same road…some take very different “trajectories” 🚦

@OncoAlert @OncoReporte
@myESMO @_SEOM @LungCancerRx @Lung_Cancers @gecp_org

[Piet Ost @piet_ost]

What a beautiful message at the end of @Mat_Guc presidency at #ESTRO26 passing the torch to @BarbaraJereczek! See you at #ESTRO27 in Milano, 21-25th of May 2027.

[ESTRO @ESTRO_RT]

🎥 Out of #ESTRO26: Can a simple blood test change the definition of oligo metastases? 🩸
🧬 Researchers found that tracking circulating tumour DNA (ctDNA) could change how we manage #oligometastaticcancer 👇@AlexSherryMD

[ESTRO @ESTRO_RT]

The OLIGOMA trial results are out! Breast #SBRT shows promising outcomes with stable patient quality of life.
Dr David Krug 🇩🇪 breaks down:
💡 Motivation for this breast cancer SBRT approach 🎯 Patient tolerance
🚀 Next steps
🎥 Watch 👇
#ESTRO26 #RadOnc #BreastCancer

[Icro Meattini @Icro_Meattini]

Congratulations @NAndratschke and the whole team - presenting @EORTC @ESTRO_RT E2-Radiate ReCare cohort to assess adequacy of patient selection #ESTRO26

Network and cooperation made the difference in science 🙏🏼💪🏼

#OncoAlert @OncoAlert

[Piet Ost @piet_ost]

@LukaszKuncman presenting maybe the most important messages for the radiation oncology community: words matter #ESTRO26

[Drew Moghanaki @DrewMoghanaki]

Largest prospective SBRT registry in the world! #ESTRO26

[OncoAlert @OncoAlert]

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨
Five-Year Follow-Up of the SABR 5 Trial: Primary Toxicity Analysis of Stereotactic Ablative Radiotherapy for Up to Five Oligometastases Presenter Robert Olson 🇨🇦

SABR-5 is a population-based phase II trial evaluating long-term toxicity of SABR for patients with up to five oligometastases. Among 380 patients treated across a provincial program, five-year follow-up showed low rates of high-grade toxicity, with no late emergence of grade ≥4 events. Most late toxicities were low grade and often persistent rather than new. These findings provide reassurance regarding the long-term safety of SABR in routine clinical practice.

#RadOnc
@ESTRO_RT
@yasemin09896924
@LindaMrissa
@christian_roenn
@Valeriadionisi
@gerryhanna
@clchiang_hk
@mtugceyilmaz
@B_Tomasik
@gmpetrianni
@CiroFranzese1
@Atem84
@piet_ost
@brachyexpert
@BlanceS90
@The_PT_Explorer
@BarbaraJereczek
@Mat_Guc
@ZilliThomas
@AnnaKirby17
@PBlanchardMD
@achoud72

Pinging OA faculty
@MKnoll_MD
@_ShankarSiva
@Icro_Meattini
@seanmmcbride
@NiuSanford
@nataliagandur
@acampsmalea
@to_be_elizabeth

[Melek Tugce Yilmaz MD @mtugceyilmaz]

Kicking off the #Oligometastatic disease channel with an excellent debate on prostate irradiation in metastatic hormone-sensitive prostate cancer! #ESTRO26!